American College of Emergency Physicians  
Clinical Policies Committee Meeting  
November 18-19, 2019  
ACEP Headquarters, Irving, TX  

MINUTES

Participants

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Chair; Richard Byyny, MD, MSc, FACEP, Methodologist; Stephen V. Cantrill, MD, FACEP, Liaison with Quality & Patient Safety Committee, and to the E-QUAL Steering Committee; Christopher R. Carpenter, MD, FACEP; Deborah B. Diercks, MD, MSc, FACEP; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP (by phone); Sigrid A. Hahn, MD, MPH (by phone); Benjamin W. Hatten, MD, MPH; Jason S. Haukoos, MD, MSc, FACEP, Methodologist; Sean M. Hickey, MD, EMRA Representative; Jon Mark Hirshon, MD, PhD, MPH, FACEP, Board Liaison; Amy Kaji, MD, MPH, PhD, Methodologist (by phone); Heemun Kwok, MD, MS, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Devorah J. Nazarian, MD; Susan B. Promes, MD, MBA, FACEP; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD; Christian A. Tomaszewski, MD, MS, MBA, FACEP; Jonathan H. Valente, MD, FACEP; Stephen P. Wall, MD, MSc, MAEd, Methodologist; Justin Winger, PhD, MA, BSN, BA, RN, PHN, ENA Representative.

Also present for all or part of the meeting: Mandie Mims, MLS, Staff Liaison; Travis Schulz, MLS, AHIP, Staff Liaison.

Agenda

1. Welcome and introductions
2. New pertinent disclosures
3. ACEP Updates
4. Comments on blunt trauma critical questions
5. Policy Pearls
6. Diversity and Inclusion
7. Strategic Assessment
9. Liaison reports
10. Community-Acquired Pneumonia Clinical Policy
11. Guideline Update
12. Opioid Clinical Policy
13. Next meeting/closing comments/other

Major Points Discussed

1. Welcome and introductions
Dr. Wolf welcomed everyone to the meeting. Participants introduced themselves.

2. New disclosures pertinent to the agenda

There were no new disclosures pertinent to the agenda.

3. ACEP Updates

ACEP staff provided updates on JACEP, MDcalc, Basecamp, and future literature searches.

4. Comments on blunt trauma critical questions

Dr. Gerardo led the discussion on the draft blunt trauma critical questions. The Committee had a lengthy discussion on the draft questions. The subcommittee chair will incorporate the edits and the Committee chair will review revised questions.

5. Policy Pearls

The committee discussed the best way to present clinical policies via various social media channels.

6. Diversity and Inclusion

Dr. Wolf led the discussion on how diversity and inclusion impacts the Clinical Policies Committee and emergency medicine. The Committee discussed the different paths to membership on the clinical policies committee.

7. Strategic Assessment

Dr. Wolf led the discussion on the review and assessment of the current policy development process. Committee members will self-select one of three work groups: Process Assessment, Stakeholder Assessment, or Methodological Assessment.


Dr. Mace led the discussion on the revisions to the policy statement. Three drafts were reviewed. The Committee came to agreement and approved one of the drafts. The approved draft will be prepared for presentation to the Board in February.

9. Liaison Reports

Dr. Tomaszewski (liaison with the Education Committee) provided a brief report on that Committee’s work.
Drs. Hatten, Lo, Valente and Mace provided updates on their work with the various American College of Radiology appropriateness criteria panels on which they serve.

Dr. Hatten reported on his work with American Dental Association.

Dr. Hickey provided an updated on his work with EMRA and the Sepsis Task Force.

Dr. Valente (liaison with the Pediatric EM Committee) provided a brief report on that Committee’s work.

Dr. Winger (ENA representative) gave an update on the current activities of the Emergency Nurses Association.

Dr. Cantrill (liaison with Quality & Patient Safety Comm. And to the E-QUAL Steering Committee) provided a brief report on that Committee’s work.

Dr. Hirshon (Board Liaison) provided an update on his work with the Board.

Dr. Lo (liaison to the EM Practice Committee) provided a brief report on that Committee’s work.

Dr. Mace (liaison to CEDR Committee) provided a brief report on that Committee’s work.

Dr. Wolf provided an update on his work with the CDC.

10. Community-Acquired Pneumonia Clinical Policy

Dr. Smith led the discussion of the CAP draft with assistance from Dr. Mace. The Committee suggested revisions to the draft. The draft will be revised and then reviewed by the Committee before being posted for open comments.

11. Guideline Update

Dr. Hickey provided an overview of the guideline titled “Diagnosis and Treatment of Adults with Community-Acquired Pneumonia: An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. Dr. Hickey also provided an overview of the guideline titled “2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS)”’. Dr. Hickey will prepare a summary of the guidelines for ACEP Now.

12. Opioid Clinical Policy

Dr. Hatten led the discussion of the opioid draft with assistance from Dr. Cantrill. The Committee had a lengthy discussion of the draft. Minor edits were suggested. The draft
will be edited and then reviewed by the Committee before being posted for open comments.